Fact-checked by Grok 2 weeks ago

Polyhydramnios

Polyhydramnios is a complication characterized by an excessive accumulation of surrounding the , typically diagnosed when the (AFI) exceeds 24 cm or the deepest vertical pocket measures 8 cm or more on . It affects approximately 1% to 2% of pregnancies, with most cases being mild and often discovered incidentally during routine mid-to-late ultrasounds. While many instances resolve without intervention, severe polyhydramnios can lead to maternal discomfort and increased risks of adverse perinatal outcomes, including and fetal anomalies. The condition arises from an imbalance in the production and resorption of , primarily influenced by fetal urine output and mechanisms. Common causes include maternal , which promotes fetal osmotic ; fetal impairments due to gastrointestinal obstructions or disorders; chromosomal abnormalities; and in multiple gestations. In about 50% to 60% of cases, no underlying cause is identified, termed idiopathic polyhydramnios. Risk factors encompass maternal conditions like diabetes and fetal anomalies affecting , with the incidence rising in the third trimester. Symptoms are often absent in mild cases but may manifest in moderate to severe polyhydramnios as , swelling in the ankles or feet, , and premature due to the enlarged . relies on fetal to quantify fluid levels, supplemented by tests such as maternal blood glucose screening, for genetic analysis, and biophysical profiles to assess fetal well-being. Severity is graded as mild ( 24-30 cm), moderate (30.1-35 cm), or severe (>35 cm), guiding management decisions. Treatment focuses on addressing underlying etiologies and monitoring progression, with mild cases typically requiring only serial ultrasounds every 1 to 3 weeks. For severe polyhydramnios, therapeutic can drain excess fluid to alleviate symptoms, though it carries risks like preterm labor; indomethacin may be used short-term to reduce fluid production in select cases. is planned at 39-40 weeks for uncomplicated mild to moderate cases, earlier for severe ones to mitigate complications such as , cord prolapse, postpartum hemorrhage, and neonatal respiratory issues. is favorable for idiopathic mild polyhydramnios, but associated anomalies worsen outcomes, with perinatal morbidity increasing alongside severity.

Introduction and Epidemiology

Definition

Polyhydramnios is a pathological condition characterized by excessive accumulation of amniotic fluid within the amniotic sac during pregnancy, leading to an abnormal increase in intrauterine fluid volume. It is typically diagnosed via ultrasonography when the amniotic fluid index (AFI) exceeds the 95th percentile for gestational age, corresponding to an AFI greater than 24-25 cm, or when the single deepest vertical pocket (SDP) of fluid measures greater than 8 cm. The AFI is calculated by dividing the uterus into four quadrants and summing the maximum vertical depth of fluid-free pockets in each quadrant, providing a semi-quantitative assessment of fluid volume. Polyhydramnios is classified by severity based on measurements into mild (25-30 cm), moderate (30.1-35 cm), and severe (>35 cm) forms, with corresponding ranges of 8-11 cm, 12-15 cm, and >16 cm, respectively. Additionally, it can be categorized as chronic, with gradual onset and progressive fluid buildup, or acute, characterized by rapid development often associated with conditions like twin-twin transfusion syndrome in monochorionic pregnancies. This classification aids in assessing associated risks and guiding management. The condition has been recognized in medical literature since ancient times, with more systematic descriptions emerging in the , linked to clinical observations of and labor complications, though diagnostic methods were limited to and invasive procedures like . Modern ultrasound-based diagnostic criteria were established in the 1980s, notably through the introduction of SDP thresholds by Chamberlain et al. in , enabling non-invasive and precise evaluation. In normal , serves essential functions, including cushioning the to permit musculoskeletal and , facilitating fetal movements that promote maturation, and aiding in by insulating against . represents a disruption of this dynamic equilibrium, where fluid production exceeds absorption or removal, potentially compromising these protective roles despite the initial excess volume.

Epidemiology

Polyhydramnios occurs in 0.2% to 1.6% of all pregnancies, with the reported varying based on diagnostic criteria such as thresholds or deepest vertical pocket measurements. This range reflects differences in study populations and detection methods, but most estimates cluster around 1% to 2%. The condition is notably more common in multiple gestations, affecting up to 10% of monochorionic twin pregnancies due to factors like twin-twin transfusion syndrome, compared to singleton rates. Approximately 65% to 70% of cases are mild, 20% moderate, and fewer than 15% severe, with mild forms often resolving without intervention. Key risk factors include over 35 years, maternal , and multifetal pregnancies, which collectively elevate the likelihood through mechanisms such as impaired glucose regulation or increased fetal urine output. Maternal diabetes, particularly gestational diabetes mellitus (GDM), is a significant associated factor, present in up to 25% of cases. Overall, the remains idiopathic in about 50% to 70% of instances, especially in mild presentations without identifiable structural or metabolic causes. Geographically, rates may be influenced by regions with elevated maternal prevalence, where higher GDM contributes indirectly. Temporally, global trends indicate a slight increase linked to rising GDM prevalence; for instance, U.S. data from the Centers for Disease Control and Prevention show GDM rising from 6.0% in 2016 to 8.3% in 2021, with continued elevation to approximately 8-9% as of 2024 due to factors like increasing . The recurrence risk in subsequent pregnancies is approximately 5% to 10% for idiopathic cases, reflecting a seven-fold relative increase over baseline but still low absolute probability. However, if polyhydramnios is associated with fetal anomalies, the recurrence risk depends on the underlying anomaly, which may reach up to 40% in some cases, necessitating enhanced prenatal surveillance in future gestations.

Pathophysiology and Causes

Pathophysiology

Amniotic fluid volume is tightly regulated through a dynamic balance between production and resorption pathways, ensuring optimal fetal development and protection. After approximately 16 weeks of , fetal urine production becomes the primary source of , contributing roughly 500–1000 mL per day by . Fetal removes about 200–500 mL per day, while occurs mainly through intramembranous pathways across the fetal membranes into the fetal circulation and, to a lesser extent, via intralung mechanisms. This equilibrium can be expressed as: net amniotic fluid change = production (primarily fetal ) − ( + ). Polyhydramnios arises from disruptions in this , leading to excess accumulation through either increased or decreased resorption. Increased often stems from fetal , such as that induced by maternal causing osmotic . Conversely, decreased resorption may result from impaired fetal swallowing, for example due to gastrointestinal obstruction. These mechanisms highlight how even subtle imbalances can escalate fluid volume, as absorption pathways like intramembranous flow adjust but may become overwhelmed. Fetal-maternal interactions play a crucial role in , mediated by aquaporins—water channel proteins expressed in the chorioamniotic membranes and —that facilitate transmembrane water transport. Excess can lead to uterine distension and myometrial stretch, altering mechanical forces on the and potentially contributing to preterm labor. In progression, mild polyhydramnios may initially remain stable, but acute cases can involve rapid fluid accumulation, elevating intra-amniotic pressure beyond 20 mmHg and heightening risks of complications.

Causes

Polyhydramnios is classified as idiopathic in approximately 50 to 60 percent of cases, particularly when mild, and these instances often resolve spontaneously without identifiable underlying pathology. Maternal factors contribute to 10 to 20 percent of cases, with being the most common, accounting for up to 20 percent overall; this occurs due to fetal inducing and increased production. Maternal infections, such as or those encompassed by the group (, other agents like , , , and ), are less frequent but can lead to polyhydramnios through fetal or impaired swallowing. Fetal structural anomalies are identified in about 20 percent of cases and typically involve conditions that hinder swallowing, such as or neural tube defects like . Chromosomal abnormalities, including trisomy 21 () and trisomy 18 (Edwards syndrome), are also significant fetal etiologies, often co-occurring with structural issues. In multiple gestations, placental factors such as twin-twin transfusion syndrome affect 5 to 10 percent of polyhydramnios cases, where the recipient twin experiences leading to polyhydramnios, while the donor twin may have ; fetal growth restriction in one twin can similarly contribute. Other causes include Rh isoimmunization, which results in fetal and high-output cardiac , thereby increasing fetal urine output and volume, though this is rare at less than 1 percent of cases.

Clinical Presentation

Symptoms

Polyhydramnios frequently manifests through subjective symptoms in pregnant individuals, though mild cases are often and discovered incidentally. These complaints arise primarily from the mechanical effects of excess , such as uterine enlargement and increased intra-abdominal pressure. Common symptoms include shortness of breath, attributed to diaphragmatic elevation by the distended uterus, which compresses the lungs; abdominal discomfort or pain due to uterine overdistension; and heartburn or gastroesophageal reflux resulting from pressure on the stomach. In severe cases, individuals may experience early satiety from gastric compression, discomfort associated with lower extremity edema, and varicose veins due to venous compression; acute polyhydramnios can present with sudden severe abdominal pain from rapid fluid accumulation. Symptoms typically emerge during the second or third and progressively worsen with advancing as volume increases. These symptoms can substantially impair , limiting daily activities and contributing to anxiety about fetal . Respiratory complaints, such as dyspnea, are particularly prevalent in symptomatic cases. Polyhydramnios is more common in pregnancies complicated by maternal diabetes, which may intensify associated symptoms.

Signs

Polyhydramnios is often identified through objective findings indicative of uterine overdistension due to excess . The uterus appears enlarged and disproportionate to , with typically measuring at least 3 cm above the expected value for gestational weeks. The may present as tense and shiny, reflecting the stretched skin and underlying fluid accumulation. On , characteristic signs include a fluid thrill elicited by percussion over the or ballotement, where the or fluid wave can be readily displaced due to the increased amniotic volume. Fetal parts may be difficult to outline clearly because of the surrounding fluid. reveals challenges in localizing fetal heart tones, which may sound distant or muffled without amplification, attributable to the insulating effect of excess fluid. Increased uterine irritability can manifest as irregular contractions palpable during examination. Vital signs may show maternal secondary to discomfort from . In severe cases, signs of preterm labor include cervical effacement and on . Associated objective signs include lower extremity from venous compression by the enlarged and maternal exceeding expected norms for .

Diagnosis

Diagnostic Methods

The diagnosis of polyhydramnios primarily relies on ultrasound imaging, which serves as the gold standard due to its non-invasive nature, real-time capabilities, and widespread availability. The (AFI) is a commonly used semiquantitative measure, calculated by dividing the into four quadrants using the maternal and umbilicus as dividers, then summing the vertical depths of the deepest cord-free pockets in each quadrant; an AFI greater than 24 cm is generally considered diagnostic of polyhydramnios in singleton pregnancies after 20 weeks' . Alternatively, the single deepest (SDP) method measures the maximum vertical depth of a single cord-free fluid , with values exceeding 8 cm indicating polyhydramnios; this approach is preferred by some clinicians as it may reduce false positives compared to AFI. For more precise volumetric assessment, three-dimensional ( can estimate total volume by acquiring multiplanar images of fluid pockets and applying the formula V = 0.52 \times L \times H \times W, where L, H, and W represent the length, height, and transverse width of the pocket, respectively; this method is particularly useful in cases where two-dimensional techniques yield borderline results. Diagnostic criteria for and are adjusted based on , as volume naturally peaks in the third trimester before declining; for instance, the 95th percentile at 28-32 weeks may reach 18-20 , while post-term values above 24 remain indicative of excess. Serial measurements are recommended to monitor progression, typically every 2-4 weeks in mild cases or more frequently if severe, to assess changes in and guide further evaluation. In complex cases, such as suspected fetal swallowing disorders or structural anomalies contributing to polyhydramnios, (MRI) provides additional detail by visualizing fetal and distribution with high soft-tissue contrast; studies from 2023 report diagnostic accuracy exceeding 90% when MRI is used adjunctively to for evaluating gastrointestinal obstructions. Historically, invasive dye dilution tests— involving injection of a dye like into the amniotic cavity followed by sampling to calculate volume—were used but have largely been abandoned due to risks of and membrane rupture, with modern imaging rendering them obsolete.

Differential Diagnosis

Polyhydramnios must be differentiated from other conditions that cause uterine enlargement or apparent excess fluid on clinical examination or initial imaging, as misdiagnosis can lead to inappropriate management. Common mimics include multiple gestations, such as twins, where increased fundal height may be mistaken for excess amniotic fluid without visualization of multiple fetuses. Large uterine fibroids can also enlarge the uterus, simulating polyhydramnios through mass effect rather than true fluid accumulation. Similarly, ovarian cysts, particularly large or cystic ones, may cause abdominal distension and be confused with amniotic fluid excess on physical exam. Maternal ascites due to liver disease, such as cirrhosis, presents with abdominal fluid accumulation that can mimic the distension seen in polyhydramnios. Key differentiators rely on and to distinguish true excess from these mimics. , using measurements like the (AFI) or deepest vertical pocket, confirms polyhydramnios by identifying anechoic fluid separate from solid masses or other collections, while targeted scans detect fibroids, cysts, or multiple sacs. Patient aids differentiation, such as gestational diabetes suggesting true polyhydramnios versus chronic conditions like cirrhosis indicating ascites. Rarer mimics include chorioamnionitis, which may present with reactive fluid changes or infection-related distension, and molar pregnancy, where hydatidiform changes create a cystic uterine appearance resembling excess fluid. Recent guidelines, including updates from 2024, emphasize genetic testing, such as chromosomal microarray, to rule out aneuploidy in cases with suspected anomalies or severe polyhydramnios, particularly when ultrasound findings are equivocal. The diagnostic algorithm begins with to quantify and assess for mimics or anomalies, proceeding to for genetic or infectious evaluation if fetal structural issues are suspected.

Management

Conservative Approaches

Conservative approaches to managing mild to moderate polyhydramnios focus on non-invasive strategies aimed at the condition, alleviating maternal symptoms, and ensuring fetal well-being without resorting to procedures. Expectant management is the cornerstone for cases without underlying fetal anomalies or severe maternal compromise, involving close observation to allow progression to term when possible. This includes serial assessments, typically performed every two weeks, to track (AFI) or deepest vertical pocket measurements and detect any progression. or activity restriction may be recommended in moderate cases to reduce uterine irritability and the risk of preterm labor, though for its is limited and it is not universally endorsed. Maternal interventions target modifiable risk factors and symptom relief. For polyhydramnios associated with , strict glycemic control is essential, with a target HbA1c below 6.5% preconceptionally and ideally under 6% during if achievable without . This is typically managed through of blood glucose (fasting <95 mg/dL, 1-hour postprandial <140 mg/dL, 2-hour postprandial <120 mg/dL) alongside dietary counseling and, if needed, insulin therapy. Dietary modifications, such as consuming small, frequent meals and reducing sodium intake, can help mitigate symptoms like abdominal discomfort, shortness of breath, and edema by promoting better fluid balance and reducing gastric pressure. Fetal surveillance is tailored to the severity of polyhydramnios. In mild idiopathic cases, routine antenatal testing is not mandatory, but for polyhydramnios with AFI ≥30 cm, the American College of Obstetricians and Gynecologists (ACOG) suggests that weekly outpatient surveillance may be considered starting at 32–34 weeks' gestation. This includes non-stress tests (NST) to assess fetal heart rate reactivity from 32 weeks onward and biophysical profile (BPP) scoring to evaluate fetal movement, tone, breathing, and amniotic fluid volume. These tests help identify any signs of fetal compromise early, guiding timely intervention if needed. Multidisciplinary care enhances outcomes by involving maternal-fetal medicine specialists for comprehensive oversight, particularly in moderate cases. Patient education is integral, emphasizing recognition of warning signs such as increased contractions, vaginal bleeding, or sudden fluid leakage to prompt immediate medical evaluation. This approach empowers patients and supports adherence to monitoring protocols.

Interventional Treatments

Interventional treatments for polyhydramnios are reserved for severe or symptomatic cases, where maternal discomfort, respiratory compromise, or risks to fetal well-being necessitate invasive interventions to alleviate excess amniotic fluid or address underlying etiologies. These approaches aim to reduce intrauterine pressure, prevent preterm labor, and improve perinatal outcomes, though they carry procedural risks and are performed at specialized centers with multidisciplinary teams. Amnioreduction, or therapeutic amniocentesis, involves the ultrasound-guided removal of excess amniotic fluid, typically 500-2000 mL per procedure, to relieve maternal symptoms such as dyspnea or abdominal pain in severe polyhydramnios (amniotic fluid index >35 cm or single deepest vertical pocket >12 cm). This intervention reduces uterine distension and the risk of preterm labor by lowering intra-amniotic pressure, with studies reporting a mean volume removed of about 1750 mL and approximately 46% of patients requiring more than one procedure; mean at delivery following amnioreduction is around 36.4 weeks. Complications occur in 1-5% of cases, including , preterm premature , , and chorioamnionitis, necessitating strict sterile technique and post-procedure . Amnioreduction is not curative and is often combined with ongoing surveillance, but it provides symptomatic relief without addressing the root cause. Pharmacotherapy with indomethacin, a (NSAID), is not recommended solely to reduce in polyhydramnios per major guidelines, though it may be used short-term before 32 weeks' gestation in other contexts such as preterm labor prevention or adjunct to amnioreduction to decrease fetal urine production. Administered orally at 25-50 mg per day for short durations (typically 2-6 weeks), indomethacin inhibits synthesis. However, its use is limited due to fetal risks, including premature closure of the , , renal insufficiency, and , particularly after 32 weeks; the 2020 FDA warning advises avoiding NSAIDs after 20 weeks' gestation unless benefits outweigh risks, and major societies like SMFM do not recommend it routinely for reduction (GRADE 1B). Close fetal and fluid monitoring are essential during therapy. When polyhydramnios stems from underlying fetal or placental conditions, targeted interventions focus on the etiology to resolve fluid excess indirectly. In twin-twin transfusion syndrome (TTTS), which frequently presents with severe polyhydramnios in the recipient twin, fetoscopic laser photocoagulation selectively ablates vascular anastomoses on the shared under and fetoscopic guidance, normalizing dynamics and improving survival rates to 60-70% for at least one twin compared to 20-30% without treatment. This procedure, ideally performed between 16-26 weeks, reduces polyhydramnios recurrence and preterm delivery risks, though complications include preterm premature rupture of membranes (10-15%) and fetal demise (5-10%). For fetal anemia causing high-output cardiac failure and polyhydramnios (e.g., due to red cell alloimmunization), intrauterine transfusion delivers compatible blood (typically 10-20 mL/kg estimated fetal weight) via -guided intravascular access, correcting levels and alleviating fluid accumulation, with survival rates exceeding 90% in experienced centers when initiated before hydrops develops. Delivery planning in severe polyhydramnios prioritizes timing and mode to balance maternal-fetal risks, often involving early or cesarean section at a tertiary care facility with neonatal intensive care capabilities. For cases beyond 37 weeks with persistent severe symptoms or complications, is recommended to mitigate risks like or abruption, achieving in most cephalic presentations; cesarean delivery is indicated for malpresentation, fetal distress, or prior uterine surgery, with overall rates around 20-30% in managed severe cases. Antenatal corticosteroids are administered if delivery before 34 weeks is anticipated to enhance maturity.

Complications and Prognosis

Complications

Polyhydramnios poses significant risks to the mother, primarily due to uterine overdistension and associated physiological stresses. Preterm premature (PPROM) is a common complication, contributing to preterm labor. is increased in pregnancies complicated by polyhydramnios, often resulting from mechanical shearing forces on the induced by excessive fluid volume. Postpartum hemorrhage is elevated due to following chronic overdistension. Additionally, severe cases can lead to from diaphragmatic compression and fluid overload, exacerbating maternal respiratory distress. Fetal and neonatal complications arise from the mechanical effects of excess amniotic fluid and resultant delivery challenges. Umbilical cord prolapse occurs particularly after membrane rupture, representing an obstetric emergency due to potential cord compression. Malpresentation, including breech position, is increased in pregnancies with polyhydramnios. Preterm birth before 37 weeks gestation is more common, driven by uterine irritability and PPROM. Stillbirth risk is increased compared to normal pregnancies in isolated polyhydramnios. Neonatal respiratory distress is also more prevalent, occurring 4.8 times more frequently in term infants with idiopathic polyhydramnios due to delayed lung maturation from reduced fetal breathing movements. Long-term neonatal outcomes are adversely affected, with increased risk of neonatal intensive care unit (NICU) admission, often linked to prematurity and respiratory issues. The underlying mechanisms involve mechanical and infectious pathways. Shearing forces from uterine overdistension can precipitate placental separation and abruption, while PPROM facilitates ascending infections, increasing chorioamnionitis risk and further compromising fetal well-being.

Prognosis

The prognosis of polyhydramnios varies significantly based on its severity and underlying , with mild idiopathic cases generally carrying a favorable outcome while severe or anomaly-associated cases are linked to higher risks of adverse perinatal events. Approximately 60% to 70% of polyhydramnios cases are mild and often idiopathic, exhibiting an excellent prognosis with many resolving spontaneously and achieving term delivery rates approaching those of normal pregnancies. In contrast, severe polyhydramnios, which accounts for less than 15% of cases, is associated with poorer outcomes, including in up to 50% of instances and increased , particularly when linked to fetal anomalies (up to 61% in malformation cases). Key influencing factors include the degree of severity, with mild cases showing about 80% uncomplicated pregnancies compared to roughly 40% for severe ones, as measured by thresholds. Underlying causes play a critical role; for instance, polyhydramnios secondary to well-controlled tends to have better outcomes with appropriate maternal glucose management, whereas cases tied to fetal anomalies like chromosomal abnormalities or impairments depend on the specific anomaly type and may elevate odds by over sevenfold. at also affects , with earlier onset in the second correlating with higher complication risks due to prolonged uterine overdistension. Long-term follow-up reveals generally positive neonatal outcomes for idiopathic cases, with potential for neurodevelopmental issues. Maternal recovery is typically complete in over 95% of cases within six weeks postpartum, barring complications like postpartum hemorrhage from , which occurs more frequently but resolves with standard care. Studies from 2024 indicate improved overall prognosis through early intervention strategies, such as targeted amnioreduction and enhanced surveillance. As of June 2025, systematic reviews confirm increased risks for preterm delivery (26%) and other complications in idiopathic cases, with overall around 4 per 1000 births.

References

  1. [1]
    Polyhydramnios - Symptoms and causes - Mayo Clinic
    Dec 5, 2023 · Learn about the symptoms, causes and treatment for this condition, in which too much amniotic fluid builds up during pregnancy.
  2. [2]
    Polyhydramnios - StatPearls - NCBI Bookshelf - NIH
    Nov 9, 2024 · Polyhydramnios is a pathological condition characterized by an excess of amniotic fluid associated with increased rates of maternal and neonatal morbidity and ...Etiology · Evaluation · Treatment / Management · Differential Diagnosis
  3. [3]
    Polyhydramnios - Diagnosis and treatment - Mayo Clinic
    Dec 5, 2023 · Learn about the symptoms, causes and treatment for this condition, in which too much amniotic fluid builds up during pregnancy.
  4. [4]
    Transient Polyhydramnios during Pregnancy Complicated with ...
    Polyhydramnios is defined as a high volume of amniotic fluid for the patient's gestational age (>95 percentile). Excess amniotic fluid cannot be clinically ...
  5. [5]
    Sonography Evaluation of Amniotic Fluid - StatPearls - NCBI Bookshelf
    Jan 22, 2025 · Amniotic fluid provides a protective environment, facilitates movement, supports temperature regulation, and contributes to the development of ...
  6. [6]
    Polyhydramnios | Radiology Reference Article | Radiopaedia.org
    May 3, 2024 · mild: a single deepest pocket at 8-11 cm or amniotic fluid index (AFI) 25-30 · moderate: a single deepest pocket at 12-15 cm or AFI 30.1-35.
  7. [7]
    Polyhydramnios - VALINTERMED treatment in Valencia
    In more modern studies of the 19th century, it became apparent that polyhydramnios could be a consequence of various diseases, both on the part of the mother ...
  8. [8]
    Historical Assessment, Practical Management, and Future ... - MDPI
    It is estimated that polyhydramnios complicates up to 1% of pregnancies; approximately half are idiopathic [42]. Polyhydramnios is most commonly associated with ...
  9. [9]
    Embryology, Amniotic Fluid - StatPearls - NCBI Bookshelf
    It provides the necessary fluid, space, and growth factors to allow normal development and growth of fetal organs such as the musculoskeletal system, ...
  10. [10]
    Polyhydramnios: Causes, Diagnosis and Therapy - PMC - NIH
    Polyhydramnios is defined as a pathological increase of amniotic fluid volume in pregnancy and is associated with increased perinatal morbidity and mortality.
  11. [11]
    Polyhydramnios - Amniotic fluid - The Fetal Medicine Foundation
    The vertical measurement of the deepest pocket of amniotic fluid free of fetal parts is used to classify polyhydramnios into mild (8–11 cm), moderate (12–15 cm) ...
  12. [12]
    Hyperglycaemia in pregnancy: the role of ethnicity and geography in ...
    Aug 4, 2025 · Significant ethnic and geographical variations exist in the prevalence and outcomes of HIP, with women from South Asia being at the highest risk ...
  13. [13]
    QuickStats: Percentage of Mothers with Gestational Diabetes... - CDC
    Jan 6, 2023 · The percentage of mothers giving birth who received a diagnosis of diabetes during pregnancy (gestational diabetes) increased from 6.0% in 2016 to 8.3% in 2021.
  14. [14]
    Prevalence and risk factors of gestational diabetes mellitus in Asia
    Dec 14, 2018 · For example, South Asian have greater odds of developing GDM than White European and Black Africa at same age [157]. Similarly, South Asian ...Missing: trends | Show results with:trends
  15. [15]
    Recurrence of idiopathic polyhydramnios: A nationwide population ...
    Oct 31, 2021 · The OR of recurrence in subsequent births increased according to IPH status in the previous births.
  16. [16]
    Regulation of amniotic fluid volume - PubMed Central - NIH
    AFV is determined primarily by the rate of intramembranous absorption (IMA) of amniotic fluid across the amnion and into fetal blood.
  17. [17]
    Polyhydramnios - Possible Causes and Next Steps - The ObG Project
    Aug 5, 2016 · Mild AFI: 24.0-29.9 cm or SDP 8-11 cm; Moderate AFI: 30.0-34.0 cm or SDP 12-15 cm; Severe AFI: ≥35 cm or SDP ≥16 cm. Recommended AFI technique.
  18. [18]
    Polyhydramnios - ISUOG
    Rhesus isoimmunization; Infections such as CMV, toxoplasmosis, rubella, parvovirus B19, syphilis, or Zika; Maternal metabolic disorders (e.g., hypercalcemia) ...
  19. [19]
    Severe polyhydramnios: incidence of anomalies - PubMed
    Twenty percent are associated with maternal abnormalities and 20% are associated with fetal anomalies. In this study, pregnancies with severe polyhydramnios ...
  20. [20]
    Polyhydramnios and Oligohydramnios - Medscape Reference
    Jun 25, 2025 · Chromosomal abnormalities, most commonly trisomy 21, followed by trisomy 18 and trisomy 13. Fetal akinesia syndrome with absence of swallowing.Background · Pathophysiology · Etiology
  21. [21]
    MC twins: TTTS - The Fetal Medicine Foundation
    Prevalence: 10-15% of monochorionic twins. Ultrasound diagnosis: There is imbalance in the net flow of blood across the placental vascular communications ...
  22. [22]
    Chronic Polyhydramnios: A Medical Entity Which Could Be a Model ...
    Jan 13, 2022 · The increased cardiac output associated with fetal anemia (for example Rh isoimmunization) can cause an increased urine production and, ...
  23. [23]
    Polyhydramnios: Causes, Symptoms, Complications & Treatment
    Polyhydramnios means there's too much amniotic fluid in your uterus during pregnancy. A mild case of polyhydramnios may not cause any symptoms or problems.Missing: SDP | Show results with:SDP
  24. [24]
    Polyhydramnios | Radiology Key
    Jul 7, 2019 · Polyhydramnios is usually chronic, but acute polyhydramnios with sudden severe increase in amniotic fluid may cause maternal dyspnea, with ...
  25. [25]
    Polyhydramnios - Gynecology and Obstetrics - Merck Manuals
    The AFI is the sum of the vertical depth of fluid measured in each quadrant of the uterus. The normal AFI ranges from > 5 to < 24 cm; values ≥ 24 cm indicate ...
  26. [26]
    Examination of the obstetric patient - Oxford Academic
    Percussion is rarely used but can illicit a fluid thrill in a case of polyhydramnios. The history and general examination will direct the specific part of the ...Missing: ballotement | Show results with:ballotement
  27. [27]
    Amniotic Fluid: Physiology and Assessment | GLOWM
    Chamberlain and colleagues arbitrarily defined polyhydramnios as a fluid pocket of at least 8 cm in vertical and transverse diameters.Missing: history | Show results with:history
  28. [28]
    Polyhydramnios | Article | GLOWM
    The increase in amniotic fluid volume is usually asymptomatic; however, the pregnant woman may experience persistent shortness of breath, uterine irritability ...
  29. [29]
    Polyhydramnios - What You Need to Know - Drugs.com
    What are the signs and symptoms of polyhydramnios? More weight gain than expected in the mother; Swelling in the legs, shortness of breath, or less urination ...Overview · Causes · Diagnosis
  30. [30]
    Amniotic Fluid Volume Assessment Using the Single Deepest ...
    An SDP measurement <1–2 cm is considered to represent oligohydramnios and an SDP measurement >8 cm represents polyhydramnios [6], [7], [8]. The ...
  31. [31]
    Three-dimensional method for determination of amniotic fluid ...
    We sought to quantify the three-dimensional volume of ultrasound-identified AF pockets, as assessed by the AFI and two-dimensional area methods.Missing: 3D formula
  32. [32]
    Polyhydramnios Imaging - Medscape Reference
    Jun 2, 2019 · The degree of polyhydramnios is frequently categorized as mild, moderate, or severe, based on an AFI of 24.0–29.9 cm, 30.0–34.9 cm, and ≥35 cm, ...
  33. [33]
    Additive value of fetal MRI to different ultrasound modalities in ...
    Mar 24, 2023 · There was 96.6% diagnostic accuracy. Table 3. Concerning postnatal results, our combined US and MRI had a 100% sensitivity, 89% specificity, ...
  34. [34]
    Historical Assessment, Practical Management, and Future ... - NIH
    Aug 10, 2024 · In the 1970s and 1980s, the application of ultrasound in obstetrics began expanding dramatically. ... ultrasound journals for polyhydramnios. jcm- ...
  35. [35]
    Polyhydramnios - Causes, Symptoms, Diagnosis, and Treatment
    Apr 25, 2025 · Healthcare providers will also consider other conditions that may mimic polyhydramnios, such as: Oligohydramnios (low amniotic fluid); Uterine ...
  36. [36]
    [PDF] Ovarian cysts complicating pregnancy - DigitalCommons@UNMC
    In some instances with marked abdom inal distention, and particuarly with large and flac cid cysts, the diagnosis of hydramnios or multiple pregnancies may be ...
  37. [37]
    Polyhydramnios: Etiology, diagnosis, and management in singleton ...
    May 2, 2024 · Outline · - All patients · - Specific issues in patients without severe polyhydramnios · - Specific issues in patients with severe polyhydramnios.Missing: chronic classification
  38. [38]
    [PDF] Polyhydramnios - MomBaby.org
    Initial Work Up. • Targeted MFM Ultrasound with special attention to growth, fetal movement & limb position,. GI, CNS, lower spine, face and palate, ...
  39. [39]
    Evaluation and management of polyhydramnios - SMFM
    The purpose of this document is to provide guidance on the evaluation and management of polyhydramnios.Missing: diagnosis | Show results with:diagnosis<|separator|>
  40. [40]
    Polyhydramnios and Oligohydramnios Treatment & Management
    Jun 25, 2025 · Medical care includes the use of steroids to enhance fetal lung maturity if preterm delivery is anticipated.
  41. [41]
    SMFM: Guidance on Reduced Activity and Bed Rest for Pregnancy ...
    May 9, 2020 · SUMMARY: Based on current evidence, SMFM provides important recommendations for the role of activity restriction and obstetric care.Missing: polyhydramnios conservative<|separator|>
  42. [42]
    15. Management of Diabetes in Pregnancy: Standards of Care in ...
    Dec 9, 2024 · Taking all of this into account, a goal of <6% (<42 mmol/mol) is optimal during pregnancy if it can be achieved without significant hypoglycemia ...Glycemic Goals in Pregnancy · Management of Diabetes in...
  43. [43]
    Gestational Diabetes Mellitus - ACOG
    The purposes of this document are the following: 1) provide a brief overview of the understanding of GDM, 2) review management guidelines that have been ...
  44. [44]
    Indications for Outpatient Antenatal Fetal Surveillance | ACOG
    The purpose of this Committee Opinion is to offer guidance about indications for and timing and frequency of antenatal fetal surveillance in the outpatient ...
  45. [45]
    Antepartum Fetal Surveillance - ACOG
    The purpose of this document is to provide a review of the current indications for and techniques of antepartum fetal surveillance and outline management ...
  46. [46]
  47. [47]
    Amnioreduction in the management of polyhydramnios complicating ...
    Amnioreduction has a useful role in the management of polyhydramnios in singleton pregnancies. Complications are uncommon, and delivery typically occurs ...
  48. [48]
    Procedure-related complications of rapid amniodrainage ... - PubMed
    Conclusions: Rapid amniodrainage using a vacuum wound-drainage system is safe and efficient to treat severe polyhydramnios, with a 3.1% complication rate.
  49. [49]
    Polyhydramnios and Oligohydramnios Medication
    Jun 25, 2025 · Most cases of polyhydramnios respond in the first week of treatment with indomethacin. This approach appears to be highly effective (90-100% ...
  50. [50]
    Treatment of symptomatic polyhydramnios with indomethacin
    We observed a significant effect of indomethacin on amniotic fluid volume and avoided severe preterm delivery in all patients. Mean gestational age at birth ...
  51. [51]
    FDA recommends avoiding use of NSAIDs in pregnancy at 20 ...
    Oct 16, 2020 · Use of nonsteroidal anti-inflammatory drugs (NSAIDs) around 20 weeks or later in pregnancy may cause rare but serious kidney problems in an unborn baby.Missing: 2025 | Show results with:2025
  52. [52]
    Balancing Benefits and Risks of Indomethacin in the Management of ...
    Jun 29, 2022 · Indomethacin is known to reduce salt wastage and subsequent polyhydramnios during pregnancy; however, it reduces the Ductus Arteriosus diameter among other ...
  53. [53]
    Endoscopic Laser Surgery versus Serial Amnioreduction for Severe ...
    Endoscopic laser coagulation of anastomoses is a more effective first-line treatment than serial amnioreduction for severe twin-to-twin transfusion syndrome.
  54. [54]
    Normalization of amniotic fluid levels after fetoscopic laser surgery ...
    Objective: The purpose of this study was to describe amniotic fluid (AF) normalization after laser surgery for twin-twin transfusion syndrome (TTTS). Methods: ...
  55. [55]
    Intrauterine transfusion in 103 fetuses with severe anemia caused ...
    Aug 2, 2022 · However, for severely anemic fetuses an IUT represents an important and in most cases life-saving treatment [12].
  56. [56]
    [PDF] Polyhydramnios-Maternal and Foetal Outcomes in Pregnancy - IJMPR
    Most common maternal complication was preterm delivery (24%). Other maternal complications were premature rupture of membranes. (16%), malpresentations (12%), ...
  57. [57]
    Placental abruption at near-term and term gestations
    Mar 23, 2023 · The acute pathway is driven by mechanical and shearing forces applied to the abdomen, causing premature placental separation. The chronic ...
  58. [58]
    Obstetric and Neonatal Outcomes in Mild Idiopathic Polyhydramnios
    In fact, they outlined higher rates of preterm delivery (54% in the polyhydramnios group vs. 5.6% in controls), postpartum hemorrhage (6.6% in polyhydramnios ...
  59. [59]
    Amniotomy at term with polyhydramnios- is the fear of umbilical cord ...
    Polyhydramnios is independently associated with increased risk of UCP after amniotomy at term. Nonetheless, the risk remains low and is not associated with ...
  60. [60]
    Obstetric and neonatal outcomes in pregnant women with idiopathic ...
    Mar 4, 2024 · This meta-analysis suggests that pregnant women with IP may be at increased risk of perinatal complications and adverse neonatal outcomes.Missing: epidemiology | Show results with:epidemiology
  61. [61]
    Polyhydramnios is an independent risk factor for perinatal mortality ...
    The incidence of premature labor was 50%. Of the various criteria examined as an independent variable, the presence of a solid tumor was found to be a ...
  62. [62]
    [PDF] Polyhydramnios
    Apr 19, 2012 · – Found a 5-fold increased risk of perinatal mortality. • A review of the literature by Magann, et al. 2007 found an overall increased risk ...
  63. [63]
    Polyhydramnios/Excess Amniotic Fluid | Birth Injury Lawyer
    Indomethacin can constrict the fetal ductus arteriosus, impair circulation, or lead to premature rupture of membranes. Physicians who go this route must monitor ...
  64. [64]
    Risk factors of cerebral palsy in children: a systematic review and ...
    Aug 6, 2025 · Background: This study aimed to explore the main risk factors for cerebral palsy in children by meta-analysis of the literature on the risk ...
  65. [65]
    Complications - The PPROM Foundation
    Bleeding is very common in PPROM. Most often bleeding comes from the placenta. Blood in fluid is like drops of red food coloring in water - the color and ...
  66. [66]
    Updated Current Management and Perinatal Outcomes of ...
    Aug 6, 2025 · Perinatal outcomes in idiopathic polyhydramnios are generally poorer, with increased risks of fetal demise, preterm delivery, and neonatal ...
  67. [67]
    Too Much of a Good Thing: Updated Current Management and...
    Polyhydramnios is defined by an AFV exceeding 2000 ml, an AFI over 24 cm, or DVP more than 8 cm. Management typically targets underlying causes, with treatments ...